MOFEZOLAC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H17NO5
Molecular Weight	339.342
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1)C2=NOC(CC(O)=O)=C2C3=CC=C(OC)C=C3

InChI

InChIKey=DJEIHHYCDCTAAH-UHFFFAOYSA-N

InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16473424
Curator's Comment: description was created based on several sources, including

Mofezolac is an NSAID ) (non-steroidal anti-inflammatory drug), which acts via the cyclooxygenase enzyme, preferentially to COX-1. It also has potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. It was introduced for the treatment of postoperative and posttraumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. It marketed only in Japan by Yoshitomi Pharmaceutical Ltd. Japan, was approved in July 1994.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9777656	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Scapulohumeral periarthritis 3 Sources: https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=004288&item_branch=001	Primary		Not Provided 504	Disopain Approved Use used to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction. Launch Date 1994
Cervicobrachial syndrome 1 Sources: https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=004288&item_branch=001	Primary		Not Provided 504	Disopain Approved Use used to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction. Launch Date 1994

PubMed

Title	Date	PubMed
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.	2002 Sep	12189188
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.	2003 Oct	14563940
Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors.	2006 Apr	16473424
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.	2006 Oct	16984374
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.	2008 Mar 18	18262365
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.	2009	19198759
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework.	2010 Jun 15	20529913

Patents

Sample Use Guides

In Vivo Use Guide

General dosage regimen (for adults): Take 1 tablet (75mg of the active ingredient) at a time three times a day after meals.

Route of Administration: Oral

In Vitro Use Guide

Mofezolac affected neither the number of TRAP-positive multinucleated cells nor the extent of lacunar resorption pits.

Name

Type

Language

MOFEZOLAC

Official Name

English

MOFEZOLAC [MI]

Common Name

English

MOFEZOLAC [JAN]

Common Name

English

3,4-BIS(P-METHOXYPHENYL)-5-ISOXAZOLEACETIC ACID

Common Name

English

MOFEZOLAC [MART.]

Common Name

English

mofezolac [INN]

Common Name

English

Mofezolac [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257